Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 3:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 639 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Relative Bioavailability Clear all

Conditions: Healthy Participants
Interventions: PF-06651600; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Hollywood, Florida • Saint Paul, Minnesota

Conditions: Healthy Volunteers
Interventions: Mitapivat tablets, Mitapivat coated granules; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: IX-01 caplets 1600 mg (4 x 400 mg), fasted, IX-01 caplets 1600 mg (4 x 400 mg), fed, IX-01 aqueous dispersion 1600 mg (20 mL), fasted; Drug
Lead sponsor: Ixchelsis Limited; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose, COMBONOX® tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Healthy Volunteers, Schizophrenia
Interventions: TAK-041, TAK-041 Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Glendale, California

Conditions: HIV Infections
Interventions: Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Finasteride 5 mg tablets, PROSCAR®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Participants
Interventions: KT-621; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Participants
Interventions: BMS-986172, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy
Interventions: Enlicitide; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tiotropium bromide inhalation solution, Placebo; Drug
Lead sponsor: Nephron Pharmaceuticals Corporation; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Rock Hill, South Carolina

Conditions: Healthy
Interventions: SSP-004184AQ, SSP-004184SS; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteers, Pharmacologic Action
Interventions: AZD3293 oral solution, AZD3293 tablet formulation A, AZD3293 tablet formulation B; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Cystic Fibrosis
Interventions: VX-121/TEZ/D-IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: Oxycodone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Alprazolam 3 mg Extended Release Tablets, single dose, XANAX XR® 3 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: Pantoprazole Sodium 40 mg delayed-release tablets, PROTONIX® 40 mg delayed-release tablets.; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 2
States / cities: Saint Charles, Missouri • Houston, Texas

Conditions: Bioavailability, Pharmacokinetics
Interventions: Fostamatinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteers
Interventions: TAK-385 T2 Formulation, TAK-385 T4 Formulation B, TAK-385 T4 Formulation C; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Chronic Hepatitis C
Interventions: telaprevir formulation A, telaprevir Formulation B, telaprevir Formulation C, telaprevir Formulation D; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Healthy
Interventions: BI 695501 - higher concentration, BI 695501 - lower concentration; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Miami, Florida • Springfield, Missouri

Conditions: Overweight and Obesity
Interventions: Maridebart Cafraglutide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Anaheim, California • Los Alamitos, California • Miami, Florida + 1 more

Conditions: Healthy
Interventions: PF-07817883, Placebo, Midazolam, Moxifloxacin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Epilepsy
Interventions: Topiramate IR, Topiramate ER; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 9
States / cities: Phoenix, Arizona • Little Rock, Arkansas • National City, California + 6 more

Search by objective public record fields.

Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.

A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants

Relative Bioavailability Study of IX-01 Caplet Versus Aqueous Dispersion and Food Effect of the Caplet in Healthy Males

A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Non-fasting Conditions

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

Finasteride 5 mg Tablets Under Fasting Conditions

A Study to Evaluate Different Oral Formulations of KT-621

A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption

A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041)

Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-004184SS (Disodium Salt)

Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects

A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers

A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions

Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions

Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets

Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection

A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations

A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People

A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)